Skip to main content
. Author manuscript; available in PMC: 2022 Mar 24.
Published in final edited form as: Br J Haematol. 2021 Feb 22;192(6):1054–1063. doi: 10.1111/bjh.17347

Figure 2.

Figure 2.

Clinical features of patients and flow cytometric immunophenotype and mutational landscape of samples with post-remission clonal hematopoiesis after NPM1 mutation clearance. Each column represents one patient/sample. FC: flow cytometry; NGS: next generation sequencing; CH: clonal hematopoiesis; MRD: measurable residual disease; PL: preleukemic immunophenotype; HMA: hypomethylating agent; Ven: venetoclax; CR: complete remission; CRi: complete remission with incomplete hematologic recovery; APL: acute promyelocytic leukemia; neg: negative; pos: positive.